title: Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment.
authors.forename: E
authors.initials: E
authors.lastname: Boix
authors.forename: P
authors.initials: P
authors.lastname: López
authors.forename: M
authors.initials: M
authors.lastname: Pérez-Mateo
authors.forename: A
authors.initials: A
authors.lastname: Picó
mesh_terms: D000208:Acute Disease; D000236:Adenoma / Q000188:drug therapy; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D006728:Hormones / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D010195:Pancreatitis / Q000139:chemically induced* / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy; D013004:Somatostatin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D006728:Hormones; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin
references.citation: Lancet. 1991 Jul 6;338(8758):52-3
references.pmid: 1676101
references.citation: South Med J. 1991 Nov;84(11):1410-1
references.pmid: 1948240
references.citation: JOP. 2003 Jan;4(1):41-8
references.pmid: 12555015
references.citation: J Clin Endocrinol Metab. 2002 Jan;87(1):99-104
references.pmid: 11788630
references.citation: JOP. 2003 Jan;4(1):33-40
references.pmid: 12555014
references.citation: J Clin Endocrinol Metab. 1997 Jul;82(7):2376-7
references.pmid: 9215324
references.citation: J Clin Endocrinol Metab. 1996 Dec;81(12 ):4502-3
references.pmid: 8954072